Effects of Conjugated Equine Estrogen on Health-Related Quality of Life in Postmenopausal Women With Hysterectomy

Authors:
  • MGMargery Gass
    Margery Gass
  • AAAaron Aragaki
    Aaron Aragaki
  • IGIris Granek
    Iris Granek
  • NWNancy Woods
    Nancy Woods
  • EMEllen Mason
    Ellen Mason
  • RBRobert Brzyski
    Robert Brzyski
  • JOJudith Ockene
    Judith Ockene
  • AAAnnlouise Assaf
    Annlouise Assaf
  • ALAndrea LaCroix
    Andrea LaCroix
  • KMKaren Matthews
    Karen Matthews

Abstract
Results of recently published large, randomized clinical trials have failed to support protective effects of oral estrogen therapy alone or estrogen plus progestin therapy on cardiovascular disease when administered to postmenopausal women.1-3 Findings of the Women’s Health Initiative (WHI)4 demonstrated that, compared with placebo, women taking conjugated equine estrogens (CEEs) were at increased risk for stroke and deep vein thrombosis and at decreased risk for osteoporotic fractures. The global risk-benefit profile was neutral in the CEE treatment group, and the planned 8.5-year randomized clinical trial (RCT) was stopped after an average of 6.8 years of follow-up (range, 5.7-10.7 years). Although the parallel WHI trial of CEE and medroxyprogesterone acetate (CEE + MPA) and other results showed that active treatment produced relief from vasomotor symptoms, the health-related quality of life (HRQOL) effects were limited to modest changes in physical functioning, sleep disturbance, and bodily pain that were considered too small to be of clinical significance on a population basis.5-7

This publication has 30 references indexed in Scilit: